Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

14,646 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Effect of First-Line Serplulimab vs Placebo Added to Chemotherapy on Survival in Patients With Extensive-Stage Small Cell Lung Cancer: The ASTRUM-005 Randomized Clinical Trial.
Cheng Y, Han L, Wu L, Chen J, Sun H, Wen G, Ji Y, Dvorkin M, Shi J, Pan Z, Shi J, Wang X, Bai Y, Melkadze T, Pan Y, Min X, Viguro M, Li X, Zhao Y, Yang J, Makharadze T, Arkania E, Kang W, Wang Q, Zhu J; ASTRUM-005 Study Group. Cheng Y, et al. Among authors: bai y. JAMA. 2022 Sep 27;328(12):1223-1232. doi: 10.1001/jama.2022.16464. JAMA. 2022. PMID: 36166026 Free PMC article. Clinical Trial.
Efficacy, Safety, and Immunogenicity of HLX04 Versus Reference Bevacizumab in Combination with XELOX or mFOLFOX6 as First-Line Treatment for Metastatic Colorectal Cancer: Results of a Randomized, Double-Blind Phase III Study.
Qin S, Li J, Bai Y, Shu Y, Li W, Yin X, Cheng Y, Sun G, Deng Y, Zhong H, Li Y, Qian X, Zhang L, Zhang J, Chen K, Kang W; HLX04-mCRC03 Investigators. Qin S, et al. Among authors: bai y. BioDrugs. 2021 Jul;35(4):445-458. doi: 10.1007/s40259-021-00484-9. Epub 2021 May 20. BioDrugs. 2021. PMID: 34014555 Free PMC article. Clinical Trial.
Efficacy and Safety of Limertinib (ASK120067) in Patients With Locally Advanced or Metastatic EGFR Thr790Met-Mutated NSCLC: A Multicenter, Single-Arm, Phase 2b Study.
Shi Y, Li B, Wu L, Pan Y, Pan Z, Liu Y, Fan Y, Ji Y, Fang J, Shi Q, Shi J, Gao H, Hu Y, Wang X, He Z, Ma R, Zhang Y, Jiang D, Bai Y, Zhang Y, Huang L, Zhou T, Liu H, Wang D, Wen Q, Chen G, Zang A, Wang X, Zhang X, Hu J, Yang R, Zhang G, Gu K, Wang L, Wang Q, Wei Z, Li Z, Lu H, Zhang H, Chen H, Song T. Shi Y, et al. Among authors: bai y. J Thorac Oncol. 2022 Oct;17(10):1205-1215. doi: 10.1016/j.jtho.2022.05.011. Epub 2022 Jun 2. J Thorac Oncol. 2022. PMID: 35659581 Free article.
[Correlation between nUGT1A1 gene polymorphisms and adverse events of irinotecan plus S-1 for patients with recurrent or metastatic esophageal squamous cell carcinoma: a prospective, open-label, randomized controlled trial (ESWN 01)].
Wang X, Liu Y, Huang JX, Lu P, Ba Y, Wu L, Bai YX, Zhang S, Feng JF, Cheng Y, Li J, Wen L, Yuan XL, Ma CW, Hu CH, Fan QX, Xu BH, Huang J. Wang X, et al. Among authors: bai yx. Zhonghua Zhong Liu Za Zhi. 2021 Nov 23;43(11):1177-1182. doi: 10.3760/cma.j.cn112152-20191022-00678. Zhonghua Zhong Liu Za Zhi. 2021. PMID: 34794220 Clinical Trial. Chinese.
[Atezolizumab therapy in Chinese patients with locally advanced or metastatic solid tumors: An open-label, phase Ⅰ study].
Zhang L, Gong JF, Pan HM, Bai YX, Liu TS, Cheng Y, Chen YC, Huang JY, Xu TT, Ge FJ, Hsu WL, Shi J, Hu XC, Shen L. Zhang L, et al. Among authors: bai yx. Beijing Da Xue Xue Bao Yi Xue Ban. 2022 Oct 18;54(5):971-980. doi: 10.19723/j.issn.1671-167X.2022.05.026. Beijing Da Xue Xue Bao Yi Xue Ban. 2022. PMID: 36241241 Free PMC article. Clinical Trial. Chinese.
14,646 results
You have reached the last available page of results. Please see the User Guide for more information.